Fermenta Biotech Sets November 5 Board Meeting for Q2 FY27

Fermenta Biotech Limited will consider its Q2 FY27 financial results at a board meeting on November 5, 2026, following a June 2026 quarter in which revenue was ₹121.82 crore and net profit was ₹9.53 crore. The announcement matters because the latest reported quarter showed broadly flat sequential revenue but lower profit.

When will FERMENTA announce Q2 FY27 results?

FERMENTA's board is scheduled to meet on November 5, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company disclosed the board-meeting intimation on October 29.

The meeting will cover the July-September 2026 quarter, described as Q2 FY27 in the company-related results schedule. The trading window was closed from October 1 ahead of the board meeting. This restriction is a routine compliance measure intended to limit trading by designated persons while unpublished price-sensitive information is being prepared for release.

The November announcement will follow the results for the quarter ended June 2026, which are the latest quarterly financial figures included in the available data. Investors will be able to compare the September-quarter outcome with both the immediately preceding June quarter and the corresponding period a year earlier once the company files its results.

What does FERMENTA's latest June 2026 quarter show?

FERMENTA reported revenue from operations of ₹121.82 crore for the quarter ended June 2026, marginally higher by 0.20% sequentially but 10.60% lower year on year. Net profit was ₹9.53 crore, down 48.76% from the preceding quarter and 55.88% from a year earlier.

Operating profit for the June quarter was ₹18.06 crore, compared with ₹20.00 crore in the March 2026 quarter. The reported operating margin was 21.0%, an improvement of 2.0 percentage points year on year. Diluted earnings per share stood at ₹5.09, while another quarterly data series reported EPS of ₹3.4; the available source material does not explain the difference in presentation.

The revenue trend shows that quarterly sales remained near the March 2026 level of ₹121.58 crore. However, the decline in net profit was sharper than the movement in revenue. The supplied quarterly data also puts EBITDA at ₹14 crore and profit before tax at ₹14.69 crore, with both figures lower than the comparable periods cited in the results commentary.

How did FERMENTA perform during FY26?

FERMENTA's consolidated revenue from operations was about ₹525 crore in FY26. The company's annual profit and loss statement reported sales turnover of ₹525.43 crore and total income of ₹547.81 crore for the year ended March 2026, compared with sales turnover of ₹469.48 crore in FY25.

Reported profit after tax for FY26 was ₹71.77 crore, versus ₹76.86 crore in FY25, according to the annual statement. A separate trailing-period summary put FY26 net profit at ₹70.25 crore and said revenue from operations grew 11.92%. These figures may reflect differences in the reporting basis used by the underlying sources, so readers should refer to the company's filed standalone and consolidated statements for the final classification.

The company reported consolidated operating cash flow of ₹92.83 crore in FY26, compared with ₹40.90 crore in FY25. Its reported free cash flow margin was 12.0% for FY26, up 3.9 percentage points from the prior fiscal year. Return on equity was 14.61% on a trailing basis to June 2026, down 8.2 percentage points from FY25.

What should investors monitor at the November board meeting?

Investors will monitor whether FERMENTA's September-quarter revenue moves above the ₹121.82 crore recorded in June and whether profitability recovers from the June-quarter net profit of ₹9.53 crore. Management's disclosures on operating profit, margins, cash generation and the reasons for any changes in costs or demand will provide important context.

Nutrition accounted for around 80% of FY26 consolidated revenue, with human vitamin D3 contributing roughly 62%, according to the available company information. India accounted for 47% of revenue, up from 35% a year earlier, while the company maintained a presence across more than 60 countries. These business exposures make the quarterly update relevant for assessing product and geographic revenue trends.

The reported share price had softened by 1.97% to ₹548.50 after the earlier update that highlighted the sequential decline in net profit. That market movement reflects the reported response to the financial update, not a forecast of the reaction to the November 5 announcement. The upcoming release will establish the next set of reported financial data for shareholders.

Conclusion

FERMENTA's November 5 board meeting is scheduled to consider Q2 FY27 results after the June 2026 quarter delivered revenue of ₹121.82 crore but a 48.76% sequential fall in net profit to ₹9.53 crore. FY26 revenue growth and stronger operating cash flow provide broader context, while the latest quarter points to pressure on earnings.

The key next event is the board's approval of unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026. Investors should watch the disclosed revenue mix, operating margin, profit trend and cash-flow commentary, particularly given nutrition's significant contribution to annual revenue.